Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Core Insights - Gilead Sciences has commenced the delivery of lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for HIV prevention as pre-exposure prophylaxis (PrEP) in Eswatini and Zambia [1] Group 1 - The deliveries are part of efforts to enhance equitable access to long-acting HIV prevention methods across sub-Saharan Africa [1] - Sub-Saharan Africa accounts for approximately two-thirds of all individuals living with HIV [1]